本帖最后由 老马 于 2012-1-13 21:20 编辑
. b* D( R0 ?3 m Q& [( r- O$ r1 }; k8 k" Y0 Q; R& ]' S$ Q0 i
爱必妥和阿瓦斯丁的比较% t# y3 X% X. W c
) _( ^+ O$ @% x0 [
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/9 k# j9 |5 |5 Y/ c
1 y4 J4 w: F- F8 p- L
3 b% V# N, h& z
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/' q' W+ `( H- n/ a/ Y
==================================================
, c7 N4 [3 [- F, _, k" D6 qOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
6 ]( A4 R; c7 J. B% MPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
- V ]& m% S: lResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
. h7 U& v. i; [) Z' z
|
显身卡
